CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 820606654
- Phone
- (650) 331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-20 | Chanda Sanjay Chief Development Officer | Grant or award · Stock Option (right to buy) | +77,000 | 77,000 | ||
| 2026-02-20 | Marks Gilbert Lynn Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Readnour Robin Shane Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Wong Stephanie Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Martin Patricia A. Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Spigelman Melvin K Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Aziz Kabeer Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | FitzPatrick Margaret M Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-02-20 | Zakrzewski Joseph S Director | Grant or award · Stock Option (Right to Buy) | +20,400 | 20,400 | ||
| 2026-01-12 | Aziz Kabeer Director | Grant or award | +11,560 | 52,479 | ||
| 2026-01-12 | Martin Patricia A. Director | Grant or award | +3,650 | 16,905 | ||
| 2026-01-12 | Marks Gilbert Lynn Director | Grant or award | +11,560 | 75,309 | ||
| 2026-01-06 | Day Lucy Chief Financial Officer | Sale | −5,512 | $1.01 | $6K | 75,363 |
| 2026-01-06 | Prior Stephen David Chief Strategy Officer | Sale | −2,858 | $1.01 | $3K | 59,086 |
| 2026-01-06 | Chanda Sanjay Chief Development Officer | Sale | −5,956 | $1.01 | $6K | 75,823 |
| 2026-01-06 | Eizen Joshua M See Remarks | Sale | −6,931 | $1.01 | $7K | 152,499 |
| 2026-01-05 | Day Lucy Chief Financial Officer | Sale | −3,295 | $1.00 | $3K | 80,875 |
| 2026-01-05 | Prior Stephen David Chief Strategy Officer | Sale | −3,604 | $1.00 | $4K | 61,944 |
| 2026-01-05 | Chanda Sanjay Chief Development Officer | Sale | −3,295 | $1.00 | $3K | 81,779 |
| 2026-01-05 | Eizen Joshua M See Remarks | Sale | −17,923 | $1.00 | $18K | 159,430 |
Page 6 of 10 · 191 trades